Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03484520 · ClinicalTrials.gov registry record · Phase 1
A Study of Venetoclax and Dinaciclib (MK7965) in Patients With Relapsed/Refractory Acute Myeloid Leukemia
A Phase 1 study, sponsored by AbbVie.
- Terminated
- Registry status
- Phase 1
- Development phase
- 48
- Enrollment target
NCT03484520 is a Phase 1 study that was terminated before completion, run by AbbVie. The registered enrollment target is 48 participants.
The verdict
NCT03484520, a Phase 1 study, was terminated before completion, sponsored by AbbVie.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 48 participants
- Enrollment target
Study Summary
An open-label, dose-escalation study to assess safety, pharmacokinetics and efficacy as well as determine the recommended Phase 2 doses of co-administered therapy of dinaciclib and venetoclax for patients with relapsed or refractory Acute Myeloid Leukemia (R/R AML).
Interventions
- DRUG Venetoclax
- DRUG Dinaciclib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2018-07-23 |
| Est. Completion | 2022-12-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03484520
The ClinicalTrials.gov registry entry for NCT03484520 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AbbVie, which has 526 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Venetoclax is the first listed.
NCT03484520 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03484520 about?
NCT03484520 is a clinical study titled "A Study of Venetoclax and Dinaciclib (MK7965) in Patients With Relapsed/Refractory Acute Myeloid Leukemia". An open-label, dose-escalation study to assess safety, pharmacokinetics and efficacy as well as determine the recommended Phase 2 doses of co-administered therapy of dinaciclib and venetoclax for patients with relapsed or refractory Acute Myeloid Leukemia (R/R AML).
What is the current status of trial NCT03484520?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 48 participants. The study started on 2018-07-23. Estimated completion is 2022-12-01.
What interventions are being tested in trial NCT03484520?
The interventions under investigation include: Venetoclax (DRUG), Dinaciclib (DRUG).
Who is sponsoring clinical trial NCT03484520?
This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.